First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Prep: Cook: Serves:

A new antipsychotic drug to treat symptoms of psychosis associated with Parkinson’s disease like hallucinations and delusions has become the first to be approved by the FDA.

The drug, called Nuplazid (pimavanserin), is the first of its kind on the market for use by people living with Parkinson’s in the US. It works only on the serotonin system, meaning – unlike previous antipsychotic medication – it doesn’t worsen motor symptoms.

It is estimated that around half the people with the condition may at some point experience hallucinations (seeing things that aren’t there) or delusions (holding false, paranoid, beliefs), also referred to as psychosis.

Dr Mitchell Mathis, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said: “Nuplazid represents an important treatment for people with Parkinson’s.”

Nuplazid is developed by Acadia Pharmaceuticals and will be available from June 2016 at the estimated annual cost of US$23,400.

Last Month

Next Month

Go Back

Share this story

Comments

Health & Fitness

Intimacy, sexuality and Parkinson’s

How to improve intimacy in couples affected by Parkinson’s

High-profile MEP supports European inventory research initiative

EPDA launches new My PD Journey research project

Developers of drug safety app want your opinion

“Help us improve patient safety," say campaigners

Regular exercise may slow progression of early Parkinson’s disease symptoms

A research team in Japan has suggested that around four hours of weekly moderate exercise is associated with a better clinical course of early-stage Parkinson’s. Their study, published in ‘Neurology’, drew on data from 237 people with the condition, whose symptoms were monitored over a period of up to six years. The research showed that people who were regularly active for at least one to two hours, one or two days a week, were better able to maintain daily activities than those who exercised less – and even experienced a “slower deterioration of processing speed”. The researchers highlighted that these benefits stemmed from maintaining regular exercise over time, rather than levels of activity at the onset of the condition. They added that their findings “suggest it may never be too late for someone with Parkinson’s to start an exercise programme”.

Could traumatic brain injury accelerate the onset of Parkinson’s disease?

Undergoing a traumatic brain injury (TBI) – a sudden injury that damages the brain – may be linked to Parkinson’s onset at an earlier age, new research suggests. The study, led by researchers in the US, examined data from the National Alzheimer’s Coordinating Centre (NACC) database and assessed whether TBI was associated with age of disease onset, survival and the degeneration of dopamine-producing nerve cells in the brain. They found that while there was no significant association with age of death or greater impact on dopamine-producing nerve cells, results showed that TBI was linked to a 4.9-year earlier age of Parkinson’s onset. Reflecting on the results, the researchers wrote that traumatic brain injury “appears to accelerate Parkinson’s onset without altering age of death”. However, the researchers also cautioned that “the nature of this relationship remains unclear”.

NASA astronaut who lived with Parkinson’s disease has died

“When I got diagnosed with Parkinson’s I thought it was over,” US astronaut Michael “Rich” Clifford once said, in a webcast conversation with Parkinson’s expert Dr Ray Dorsey. But when US space agency NASA offered him another opportunity to board a space shuttle, despite the onset of Parkinson’s symptoms, he didn’t hesitate. “And it was as easy as that.” Now, nearly 30 years since his final venture into space, Clifford has died due to complications from Parkinson’s disease. He leaves a legacy of three journeys into space, several awards for his services to the space programme – including the NASA Space Flight Medal – and a history of advocacy for people with Parkinson’s. In a 2013 conversation with the Michael J Fox Foundation, Clifford said: “Everyone with Parkinson’s handles it differently. Don’t let it get in the way of living. “Life is too good. Keep going. The sky’s the limit.” Image credit:…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Health & Fitness

Intimacy, sexuality and Parkinson’s

Europe

High-profile MEP supports European inventory research initiative

Advances

Developers of drug safety app want your opinion

Regular exercise may slow progression of early Parkinson’s disease symptoms

Could traumatic brain injury accelerate the onset of Parkinson’s disease?

NASA astronaut who lived with Parkinson’s disease has died

{title}

Subscribe

First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Last Month

Next Month

Share this story

Comments

Related articles

Health & Fitness

Intimacy, sexuality and Parkinson’s

Europe

High-profile MEP supports European inventory research initiative

Advances

Developers of drug safety app want your opinion

Regular exercise may slow progression of early Parkinson’s disease symptoms

Could traumatic brain injury accelerate the onset of Parkinson’s disease?

NASA astronaut who lived with Parkinson’s disease has died

{title}

Subscribe

Sign in